Access widened to funded medicines

Last updated 05:00 13/11/2012

Relevant offers

Politics

Damning Afghanistan war report criticises lack of planning for NZ deployment Bill English says SAS inquiry unlikely after Defence Force attacks Hit and Run 'inaccuracies' Defence Force chief slams 'major inaccuracies' in SAS Afghanistan allegations ACT leader David Seymour says party can't afford any 'screw-ups' Labour accuses Government of planning to 'asset-strip' state houses from regions Ratings agency Moody's gives NZ economy highest possible rating Stacey Kirk: lessons applicable to life, as taught by John Key Alison Mau: I'm a republican, yet now, we need the Queen more than ever Oscar Kightley: My brother served in the army, I nearly served – but nobody signed up to kill civilians David Slack: Nothing says vomit like an Air New Zealand sickbag

Pharmac has spent more than $21.5 million on new drugs and widening access to publicly funded medicines in the past year.

Blood thinning drug Pradaxa, also known as dabigatran, was the most expensive new drug to be funded, with an estimated annual cost of $16 million.

Two new drugs targeting specific types of breast and kidney cancer were also added to the list of funded medications.

More people can access the drug rituximab, which is used to treat some kinds of lymphomas. Breast cancer drug docetaxel has also been made more widely available and access to funded treatment for Crohn's disease, Cystic fibrosis and asthma were widened.

The Government's drug-buying agency yesterday released its annual report for the year ending June 30, which showed 14 new medicines were funded in the past year and access to 10 others was widened.

An extra 56,840 patients were expected to benefit from the changes, on top of the record 3.3 million New Zealanders who received fully funded medication in the past year.

Pharmac stayed within its $777.4m budget in a year which saw it take on additional roles, including managing the national immunisation schedule and hospital medicines and medical devices.

It also contributed $379,000 towards a research trial in Finland looking at whether the nine week or 12-month duration of breast cancer drug Herceptin offers a better treatment.

Ad Feedback

- The Dominion Post

Special offers
Opinion poll

Where do you stand on political coat-tail riding?

If it gets marginalised voices into Parliament, I'm for it.

I'm against it - if you don't get the votes, you shouldn't be there.

It's just part of the political game.

Vote Result

Related story: Voters reject riding on the coat-tails

Featured Promotions

Sponsored Content